Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab-Reference-Cited by-同舟云学术

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab

Published:2015-11 Issue:17 Volume:51 Page:2689-2697
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Eroglu Zeynep,Kim Dae Won,Wang Xiaoyan,Camacho Luis H.,Chmielowski Bartosz,Seja Elizabeth,Villanueva Arturo,Ruchalski Kathleen,Glaspy John A.,Kim Kevin B.,Hwu Wen-Jen,Ribas Antoni

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference38 articles.

1. Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma;Kaufman;J Clin Oncol,2014

2. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N Engl J Med,2010

3. Checkpoint blockade in cancer immunotherapy;Korman,2006

4. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application;Ascierto;J Transl Med,2011

5. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma;Annals of Oncology;2024-05

2. PIEZO1 mechanically regulates the antitumour cytotoxicity of T lymphocytes;Nature Biomedical Engineering;2024-03-21

3. The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers;Biomarker Insights;2024-01

4. The clinicopathological impact of tumor‐associated macrophages in patients with cutaneous malignant melanoma;Journal of Surgical Oncology;2023-11-02

5. Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments;Journal of Personalized Medicine;2023-07-13